Double Bond Pharmaceutical International AB (XSAT:DBP B) Quality Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSAT:DBP B Double Bond Pharmaceutical International AB XSAT:DBP B
29 GF Score
Price kr0.15
GF Value kr0.06
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Double Bond Pharmaceutical International AB Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Double Bond Pharmaceutical International AB Quality Rank Related Terms

XSAT:DBP B
29GF Score
Double Bond Pharmaceutical International AB XSAT:DBP B
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Double Bond Pharmaceutical International AB (XSAT:DBP B) Overvalued in 2026?

Based on GuruFocus' analysis, Double Bond Pharmaceutical International AB stock appears to be overvalued. The current stock price of kr0.15 is trading 152.5% above its estimated GF Value™ of kr0.06. GuruFocus considers Double Bond Pharmaceutical International AB to be Significantly Overvalued.

Key valuation signals for XSAT:DBP B:

  • Quality Rank:
  • GF Value™: kr0.06 vs. price of kr0.15 (152.5% above fair value)
  • GF Score™: 29/100 with 3 warning signs

No single metric tells the full story. See the XSAT:DBP B stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Double Bond Pharmaceutical International AB Business Description

Address Virdings Alle 32B, Uppsala, SWE, 75450
Double Bond Pharmaceutical International AB is a pharmaceutical company. The company develops and commercializes approaches for the treatment of cancers, infections, autoimmune diseases, and other life-threatening disorders.
29GF Score

Get the complete analysis for XSAT:DBP B

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.15
Price
kr0.06
GF Value